Pep2Tango Therapeutics is a technology company.
Pep2Tango Therapeutics has raised $1K across 1 funding round.
Pep2Tango Therapeutics has raised $1K in total across 1 funding round.
Pep2Tango Therapeutics is not a technology company—it is a biotechnology company focused on developing next-generation peptide drugs for obesity and related metabolic disorders.
Pep2Tango Therapeutics is a privately-held biotech startup developing unimolecular multi-receptor agonist peptides designed to treat obesity while preserving muscle mass.[1] The company's core mission is to create next-generation weight loss therapies that address unmet medical needs in metabolic, endocrine, CNS, and cardiovascular disorders.[1]
The company serves patients with obesity and related conditions, tackling a critical problem: existing weight loss medications often cause muscle loss alongside fat loss and face manufacturing and tolerability challenges.[4] Pep2Tango's approach aims to deliver superior efficacy compared to current market leaders like tirzepatide (Zepbound) through a differentiated mechanism that combines four receptor targets into a single molecule.[1][4]
Pep2Tango was founded in 2021 by seasoned pharmaceutical executives with deep expertise in drug development.[1] The company is led by CEO and Chairperson Cristina Rondinone, Ph.D., who previously oversaw cardiometabolic drug development at AstraZeneca and served as president of startup Cellarity.[4] Chief Scientific Officer Soumitra Ghosh, Ph.D. formerly led R&D at Amylin Pharmaceuticals, a company that developed pioneering GLP-1 drugs for diabetes.[4]
The startup emerged from stealth in late 2024 backed by Versant Ventures, a prominent biotech venture firm known for launching and scaling biotech companies.[1] The founding team's vision centered on developing a "tetra-agonist"—a first-in-class approach that Rondinone described as moving beyond the conventional mono, dual, or triple agonist strategies already in development.[4]
Pep2Tango operates within the rapidly expanding obesity therapeutics market, riding the wave of GLP-1 agonist success while pushing toward next-generation solutions.[4] The company represents a broader industry trend of moving beyond first-generation weight loss drugs to address their limitations—particularly muscle loss and manufacturing complexity.
The timing is strategic: as tirzepatide and semaglutide dominate the market, biotech investors are funding differentiated approaches that promise improved efficacy and tolerability.[4] Pep2Tango's tetra-agonist strategy positions it as a potential category leader if clinical data validates preclinical findings, influencing how the industry approaches multi-target drug design for metabolic diseases.
Pep2Tango is entering IND-enabling studies with its first-in-class obesity medicine, positioning it for clinical trials in the near term.[1] The company's success hinges on translating preclinical advantages into clinical efficacy and navigating the competitive obesity therapeutics space, where multiple well-funded competitors are pursuing similar multi-target strategies.
If Pep2Tango's tetra-agonist approach proves clinically superior while maintaining safety and tolerability, it could reshape obesity treatment standards and validate the multi-receptor peptide platform for other metabolic and endocrine disorders—the company's stated long-term vision.[1]
Pep2Tango Therapeutics has raised $1K in total across 1 funding round.
Pep2Tango Therapeutics's investors include Avalon Ventures, Polaris Partners, Versant Ventures.
Pep2Tango Therapeutics has raised $1K across 1 funding round. Most recently, it raised $1K Venture Round in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $1K Venture Round | Avalon Ventures, Polaris Partners, Versant Ventures |